ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Jun 12, 2019 15:00 JST
Source:
Alset International Ltd
Global BioLife's 3F Mosquito Repellent Formula performs well in Independent Testing
SINGAPORE, Jun 12, 2019 - (ACN Newswire) - SGX-listed Singapore eDevelopment Ltd (SeD) wishes to announce that U.S. biomedical subsidiary Global BioLife Inc. has independently tested its new 3F Mosquito Formula which performs well against mosquitoes for six (6) to eight (8) hours.
In 2017, SeD announced a collaboration between Global BioLife and U.S. based Chemia Corporation to develop a suite of fragrances referred to as 3F (Functional Fragrance Formulation). Previous testing was promising for the 3F Mosquito Fragrance, which is made of specialised oils sourced from botanicals that mosquitoes avoid in varying concentrations of 0.25% to 5%.
Global BioLife contracted U.S. based Snell Scientifics, LLC in Meansville, Georgia to conduct a study on the new mosquito repellent formula and the results of the study showed that it repelled between 82% to 95% of mosquitos for six (6) hours after application.
"Utilising fragrances to repel mosquitos with this level of efficacy is a game changer for the consumer products industry," said Mr. Thomas A. Meyer, Chemia's Vice-President of Innovation and Sustainability.
Globally, an estimated 3.4 billion people in 92 countries are at risk of being infected with Zika, Dengue, West Nile Virus, Malaria and other mosquito transmitted diseases. Mosquito repellent products are key in the fight against mosquito transmitted diseases, while a product favoured by consumers is easy to apply, is considered safe, and does not have unpleasant attributes such as a strong chemical odour.
The market for safe mosquito repellents is expanding, and consumers have expressed a demand for effective mosquito repellent products with appealing scents. The most recently tested product has a fragrance that is modeled on the fresh scent of the Ghost Orchid, a rare flower known for its distinctive and pleasant aroma found in the Everglades of Florida.
"3F Mosquito works differently from traditional insect repellents. It's effective even at very low concentrations due to its multi-aspect receptor inhibition," said Mr. Daryl Thompson, Global BioLife's Director of Scientific Initiatives.
"Global BioLife is extremely proud of these test results," said SeD's Executive Chairman Mr. Chan Heng Fai. "3F is an innovative product that works in an entirely different manner from any other product on the market today. 3F is a true success for people everywhere and will help reduce the number of mosquito transmitted diseases on a global scale."
Global BioLife is currently in discussions with interested companies for potential licensing and global deployment of this new mosquito repellent formula.
About Singapore eDevelopment Limited
Incorporated on 9 September 2009 and listed on the Singapore Exchange in July 2010, Singapore eDevelopment Limited is involved in (i) property development and investments primarily in the United States and Western Australia; (ii) information technology-related businesses; (iii) development, research, testing, manufacturing, licensing and distribution of biomedical products; and (iv) investment activities. For more information, please visit: www.SeD.com.sg or email
contact@sed.com.sg
.
About Global BioLife Inc.
Global BioLife Inc. ("GBLI") is a 70%-held direct subsidiary of Global BioMedical Inc., which is a wholly-owned direct subsidiary of Singapore BioMedical Pte. Ltd., which in turn is a wholly-owned direct subsidiary of Singapore eDevelopment Limited, a company listed on the Singapore Exchange. The remaining shareholding of Global BioLife Inc. is held by Global Research and Discovery Group Scientific LLC ("GRDGS") at 20% and Australian Exchange-listed Holista CollTech Limited ("Holista") at 10%. For more information, please visit:
http://www.globalbiolife.com
.
About GRDG Sciences, LLC.
GRDG Sciences, LLC is an advanced research team formed in Florida by natural products discovery drug research scientist, Daryl Thompson. For more information, please visit:
http://www.globalrdg.com
.
Source: Alset International Ltd
Sectors: Healthcare & Pharm, Cosmetics, Spec.Chem
Copyright ©2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
Fujitsu and 1Finity to highlight latest network technologies and AI solutions at MWC Barcelona 2026
Feb 13, 2026 22:50 JST
Fujitsu to present latest technologies for creating social and industrial value through fusion of AI and computing at India AI Impact Summit 2026
Feb 13, 2026 22:33 JST
Mitsubishi Power Hosts Inaugural Energy Forward Forum in Indonesia with Government and Industry Experts
Feb 13, 2026 22:24 JST
MHI Successfully Demonstrates Production of Liquid Synthetic Fuels through an integrated Process Utilizing SOEC Co-Electrolysis and FT Synthesis
Feb 13, 2026 22:03 JST
JCB Sponsors the NHK Symphony Orchestra Singapore Concert 2026 - Celebrating 60 Years of Singapore-Japan Relations
Feb 13, 2026 14:00 JST
Lockheed Martin and Fujitsu Formalize Industrial Collaboration for Japan Defense
Feb 12, 2026 19:59 JST
Meiji and Fujitsu launch world's first rRAFU(TM) pilot to assess future malnutrition and frailty risk
Feb 12, 2026 16:09 JST
Fujitsu Group starts manufacturing sovereign AI servers in Japan to enhance digital sovereignty
Feb 12, 2026 12:13 JST
Premiere of Three-Row Highlander BEV in North America
Feb 11, 2026 14:25 JST
Honda Works Partner Aston Martin Aramco Formula One(TM) Team Unveils Livery of "AMR26" F1(TM) Machine Equipped with Honda Power Unit Ahead of the 2026 Race Season
Feb 10, 2026 18:25 JST
Honda to Make Organizational Changes to Further Enhance Competitiveness its Motorcycle, Automobile and Power Products Business
Feb 10, 2026 17:53 JST
KS Energy and Hitachi Collaborate on Extra-High Voltage Battery Energy Storage System
Feb 10, 2026 14:15 JST
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China
Feb 10, 2026 13:34 JST
NEC Exhibits at MWC Barcelona 2026, the World's Largest Mobile-Related Exhibition
Feb 09, 2026 21:18 JST
CITIC Telecom CPC Wins Two Awards, Celebrating 'Innovation Never Stops' for 25 Years, recognizing Cybersecurity & Innovation Excellence
Feb 09, 2026 14:28 JST
JCB Announces Collaboration with Resorts World Sentosa in Singapore
Feb 09, 2026 14:00 JST
Anime Tokyo Station: "That Time I Got Reincarnated as a Slime" Special Exhibition, February 21 to May 24, 2026
Feb 09, 2026 11:00 JST
Mitsubishi Motors Launches the All-New Versa Van in the Philippine Market
Feb 06, 2026 13:34 JST
Establishment of the World's First*1 Global Supply Chain to Introduce the Use of Renewable Plastics in Sony's High-Performance Products
Feb 06, 2026 11:50 JST
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
Feb 06, 2026 11:31 JST
More Latest Release >>
Related Release
Alset International Ltd establishes Alset Mining Pte Ltd to embark on cryptocurrency mining activities
March 23 2022 09:00 JST
Alset Capital Acquisition Corp. Announces Closing of Initial Public Offering and Exercise of Full Over-Allotment Option
February 21 2022 12:00 JST
Impact BioMedical to Begin Efficacy Testing Pan-Coronavirus Vaccine Under New Wholly Owned Subsidiary Innate Immune, Inc.
October 05 2020 15:25 JST
Impact BioMedical Demonstrates 10-Fold Reduction in Viral Population of COVID-19 in Surface Disinfectant Efficacy Testing of its 3F Antiviral Biofragrance
September 18 2020 17:00 JST
Impact Biomedical initiates Quantum, a new frontier in Pharmaceutical Development
July 31 2020 15:00 JST
Impact Biomedical Achieves COVID-19 Success with Equivir and 3F Biofragrance
June 24 2020 14:00 JST
Impact Biomedical Announces Publication of COVID-19 Research in Peer-Reviewed Journal
June 17 2020 18:00 JST
Impact Biomedical and GRDG Sciences Announce Medical Technology Package Valued at USD 1.39 Billion (SGD 1.97 Billion) by Independent Experts
June 01 2020 13:00 JST
Impact Biomedical's Majority Owned Next Generation Medical Technologies Valued at USD 592 Million (SGD 841 Million) by Independent Experts
April 24 2020 10:00 JST
Impact BioMedical's Linebacker and Equivir inhibit SARS-CoV-2, virus responsible for the COVID-19 outbreak
March 18 2020 11:00 JST
More Press release >>